NC // Decision Intelligence powered by Claim Forensics

Disputed healthcare claim under review?

Identify evidence stabilization 100–400 days before institutional action. Get source-backed intelligence showing what changed, what holds, and what moves the needle.

NextConsensus produces high-discipline decision briefs for coverage, regulatory, safety, and diligence reviews. Delivered as a 1-page, auditable specimen.

Scope One Claim
Context One Decision
Velocity 24h Alignment Check

Public lane note

finerenone / albuminuric CKD
Phase 2: Validated
Finerenone Lead 104 days (Gradual Build)
Semaglutide Lead 214 days (Early Spike)
Pluvicto Lead 389 days (Early Spike)
Pattern Detected Consensus Silence
This is the visible boundary: proof work can continue, but public numeric claims wait for the validation gate. View the lane note
Claim Forensics: Illustrative
CLAIM Finerenone 2024 · Semaglutide 2019
LANE SGLT2 / HF + CKD
VALIDATED 2026-05-04
METHOD v4.2

Live Inventory

Hardened Evidence Lanes

Evidence Lane Context Lead Time Score Status
Finerenone CKD / Payer 104d (Gradual) 0.68 Hardened
Semaglutide GLP-1 / Supply 214d (Spike) 0.87 Hardened
Pluvicto Oncology / RLT 389d (Spike) 0.90 Hardened
Enhertu Oncology / HER2 120d+ 0.90 Screened
Efgartigimod gMG / FcRn 90d+ 0.88 Screened

02 // THE OUTPUT

A disciplined, falsifiable decision memo.

The brief is the core product. It is built for teams that need to make decisions while the evidence record is still moving.

Specimen Format 1-Page Decision Brief
  • Window Status: Open / Narrowing / Closing
  • What Changed: Trajectory of evidence shifts
  • What Holds: Stable evidence supporting the read
  • What Is Under Stress: Contested evidence points
  • What Would Reverse: Reversal conditions

03 // YOUR CONTEXT

Built for five review contexts.

NextConsensus indexes evidence shifts by decision triggers, identifying which changes materially change the read for specific review types.

Coverage

Payer policy, Medicaid, and coverage determination reviews

Formulary

P&T committee dockets and formulary exclusion challenges

Regulatory

FDA label updates, briefing documents, and advisory meetings

Safety

Safety communications, risk management, and signal surveillance

Diligence

Asset valuation, licensing, and pre-acquisition evidence audits

04 // THE TIMING

Evidence moves before institutions act.

We track the mismatch between evidence movement and institutional timing. In drug safety, regulatory, and coverage reviews, the record often stabilizes months before the formal recognition event.

"What would reverse the read?" We identify the specific evidence shifts that would materially change the conclusion.

Two curves showing evidence stabilization preceding institutional recognition, with a shaded window of movement between them
Measured lead time varies by evidence pattern (100–400 days). We track whether the gap is open, narrowing, or closing.
Commercial Alpha Capture "The Lag"

Capture generic entry signals 90+ days early, optimize formulary submission timing, or detect safety signals before they hit the headlines.

Validated Specimens

Proven Lead Times

Independent out-of-sample audits confirm evidence stabilization precedes institutional action by 100 to 400 days.

finerenone / albuminuric CKD 104 days (Gradual Build) Lead

Signal detected absence of change (hardening) 3 months before outcome.

semaglutide / obesity 214 days (Early Spike) Lead

Hardening spike triggered by concentrated clinical data stabilization.

pluvicto / prostate cancer 389 days (Early Spike) Lead

Stabilized consensus detected 1 year before broad institutional recognition.

05 // TRUST ARCHITECTURE

Restraint is a feature.

The validation boundary is part of the product. We do not predict outcomes. We do not promote unsupported claims. If the evidence is not strong enough to support a read, the brief says so plainly.

Institutional Grade No Prediction

We do not predict institutional outcomes. We provide the source-backed record so your team can make the call with zero hallucination risk.

Claim Control Frozen Public Claims

Public numeric claims remain frozen until production backtest gates are cleared. Private briefs carry explicit lineage and caveats.

Transparency Auditable Lineage

Every read is linked to a specific versioned measurement artifact and source snapshot.

Start

Have one claim, one review date?

We still have time to make a better call — but not indefinitely. Send the claim, the decision context, and the review date. We respond within one business day with fit, limits, and next steps.

Requests for sourced specimens require a verified institutional email address and are subject to the current lane authorization limits.

Today's Read finerenone-cardiorenal
Hardening
Signal 0.38 / Gate 0.65
Phase 1b pending review. Other lanes: dossier-build.

Visual Debug

Page:

Width: px

Theme: